🔎 Trials Near Me

ホーム › 急性骨髄性白血病 › ペンシルベニア › Pittsburgh

Pittsburgh、PAにおける急性骨髄性白血病の臨床試験

Pittsburghとその周辺地域(約30マイル以内)の拠点で、急性骨髄性白血病に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト(英語)

ここで研究参加者を募集していますか? このページの上部に表示できます — 30日間 $99 →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

被験者募集中第2相
  • UPMC Hillman Cancer Center, Pittsburgh
18歳以上 · 全性別 · 2026/10/05更新 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

被験者募集中第1相
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh
21歳以下 · 全性別 · 2026/10/05更新 · NCT07012044

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

被験者募集中第3相
  • University of Pittsburgh Medical Center, Pittsburgh
18歳以上 · 全性別 · 2026/09/25更新 · NCT06852222

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

被験者募集中第2相
  • UPMC Hillman Cancer Center, Pittsburgh
18歳以上 · 全性別 · 2026/09/22更新 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

被験者募集中第2相
  • UPMC Hillman Cancer Center, Pittsburgh
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

被験者募集中第2相
  • UPMC Hillman Cancer Center, Pittsburgh
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

被験者募集中第3相
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562

A Study of BGB-11417 in Participants With Myeloid Malignancies

被験者募集中第1/2相
  • Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
18歳以上 · 全性別 · 2026/09/14更新 · NCT04771130

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

被験者募集中第3相
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh
1歳〜25歳 · 全性別 · 2026/09/04更新 · NCT07022678

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

被験者募集中第3相
  • US-Pittsburgh PA-PITT, Pittsburgh
18歳以上 · 全性別 · 2026/09/02更新 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

被験者募集中第3相
  • US-Pittsburgh PA-PITT, Pittsburgh
18歳以上 · 全性別 · 2026/09/01更新 · NCT07223814

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

被験者募集中第1相
  • UMPC Hillman Cancer Center, Pittsburgh
18歳以上 · 全性別 · 2026/08/18更新 · NCT07565220

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

被験者募集中第2相
  • UPMC Hillman Cancer Center, Pittsburgh
18歳以上 · 全性別 · 2026/08/11更新 · NCT06529731

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

被験者募集中観察研究
  • Children's Hospital of Pittsburgh, Pittsburgh
  • West Penn Hospital, Pittsburgh
  • University of Pittsburgh Medical Center, Pittsburgh
  • 他1件
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

被験者募集中第1/2相
  • Allegheny Health Network, Pittsburgh
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

被験者募集中第2相
  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
1歳〜60歳 · 全性別 · 2026/03/12更新 · NCT03970096

他の都市における急性骨髄性白血病の試験

Pittsburghにおける他の研究

ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。